Analyst consensus rating
ANI Pharmaceuticals Analyst Rating: Buy
Direct answer
ANI Pharmaceuticals's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $105.22.
Forecast evidence checked November 12, 2026.
Get free ANI Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $71.09
- Average price target
- $105.22
- High price target
- $121.00
- Low price target
- $85.00
- Low target gap
- +19.6%
- Target upside
- +48%
- High target gap
- +70.2%
- Target range width
- 50.6%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ANI Pharmaceuticals?
ANI Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $105.22.
How far are ANI Pharmaceuticals's low and high targets from the recorded price?
The low target implies +19.6%, while the high target implies +70.2%.
How many analysts are included in ANI Pharmaceuticals's consensus?
The verified consensus includes 9 analysts.
How is ANI Pharmaceuticals's target upside or downside calculated?
The average target of $105.22 is divided by the recorded price of $71.09, then one is subtracted to produce +48%. This does not guarantee a future return.
When was ANI Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.